Aterocard

Secondary prevention of atherothrombosis in adults:

• in patients who have had a myocardial infarction (treatment should be started in a few days, but not later than 35 days after the onset), ischemic stroke (treatment should be started in 7 days, but not later than 6 months after the onset) or who have been diagnosed with peripheral arterial disease (arterial lesions and atherothrombosis of the lower extremities);
• in patients with acute coronary syndrome:
  • with acute coronary syndrome without ST-segment elevation (unstable angina or myocardial infarction without Q-wave), including in patients who have had a stent installed during percutaneous coronary angioplasty in combination with acetylsalicylic acid (ASA);
  • with acute ST-segment elevation myocardial infarction in combination with ASA (in patients receiving standard medical treatment and who are indicated for thrombolytic therapy).

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation.

Clopidogrel in combination with ASAs is prescribed for adult patients with atrial fibrillation who have at least one risk factor for vascular events, who have contraindications to treatment with vitamin K antagonists (VKAs) and who have a low risk of bleeding, to prevent atherothrombotic and thromboembolic events, including stroke.